EGFR overexpression and chromosome 3p deletion are two frequent events in head and neck cancers. We previously mapped the smallest region of recurrent copy-number loss at 3p12.2-p14.1. LRIG1, a negative regulator of EGFR, was found at 3p14, and its copynumber loss correlated with poor clinical outcome. Inducible expression of LRIG1 in head and neck cancer TW01 cells, a line with low LRIG1 levels, suppressed cell proliferation in vitro and tumor growth in vivo. Gene expression profiling, quantitative RT-PCR, chromatin immunoprecipitation, and western blot analysis demonstrated that LRIG1 modulated extracellular matrix (ECM) remodeling and EGFR-MAPK-SPHK1 transduction pathway by suppressing expression of EGFR ligands/activators, MMPs and SPHK1. In addition, LRIG1 induction triggered cell morphology changes and integrin inactivation, which coupled with reduced SNAI2 expression. By contrast, knockdown of endogenous LRIG1 in TW06 cells, a line with normal LRIG1 levels, significantly enhanced cell proliferation, migration and invasiveness. Such tumor-promoting effects could be abolished by specific MAPK or SPHK1 inhibitors. Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) and oral squamous cell carcinoma (OSCC) are two major subtypes of head and neck cancers. Genetic susceptibility, viral infection and chemical exposure have been suggested as risk factors for development of these human malignancies. 1 Enhanced genome instability with gross chromosomal abnormalities has been directly correlated with tumor recurrence and metastasis of NPC, 2, 3 leading to high mortality and low five-year overall survival, which have not been improved in decades. 4 Understanding of the molecular mechanisms involved in the development of advanced head and neck cancers will help in clinical management and drug discovery. Genome-wide surveys and clinical association studies have identified two recurrent copy-number aberrations, 3p deletion (3p12.3-p14.2) and 3q amplification (3q26.2--26.32), with prognostic value for metastatic NPC. 3 Notably, chromosome 3p loss is also a genetic hallmark in other types of head and neck cancers 5, 6 and has been defined as a crucial early event in NPC progression. 7 These findings suggest that potent tumor suppressors may be encoded within the 3p deletion region, 3p12.3-p14.2.
LRIG1, a negative regulator of EGFR mapping to 3p14, encoding a transmembrane protein containing fifteen leucine-rich repeats and three Ig-like domains in its extracellular region, has been proposed as a tumor suppressor gene, 3, 8 and shown to be downregulated in several tumor types, for example, renal cell carcinoma, 9 advanced cervical cancer, 10 glioma 11 and breast cancer. 12, 13 In addition, LRIG1 downregulation correlates with higher tumor grade and a worse outcome in human squamous cell carcinoma 14 and breast cancer. 15 Currently, the tumor suppressive function of LRIG1 is mainly attributed to its inhibitory effect on EGFR signaling. Over the past few years, it has been shown that LRIG1 binds to EGFR and attenuates EGFR signaling via both receptor degradation and catalytic inhibition. 16 Moreover, soluble ectodomains of LRIG1 are sufficient to reduce EGFR activity via shedding of the leucine-rich repeats region and Ig-like domains. 17, 18 Ectopic expression of LRIG1 on the other hand, inhibits cancer cell motility and invasiveness of EGFR ( þ ) prostate cancer cells 19 and EGFRvIII ( þ ) glioblastoma cells. 11, 20 Besides ErbB family, functions of other receptor tyrosine kinases like Met and Ret have been reported to be regulated by LRIG1 via cbl-independent degradation mechanism. 21, 22 These findings imply that LRIG1 may have an anti-metastatic role in human cancers.
Although constitutive activation or overexpression of EGFR is frequently found in head and neck cancers, 23 ,24 molecular mechanisms underlying functional roles of LRIG1 in head and neck cancer remain elusive. The present study demonstrates LRIG1 expression as significantly lower in NPC and OSCC tumors than in their non-tumor counterparts. Lower LRIG1 levels in NPC patients are prognostic for poor survival. Using a Tet-off inducible system in NPC cells, we demonstrated anticancer effects both in vivo and in vivo, triggered by LRIG1 induction. Using cDNA microarrays, we probed the signaling network regulated by LRIG1 expression in head and neck cancers, with validated results by chromatin immunoprecipitation (ChIP), antibody array, western blot and fluorescent immunostaining. To mimic clinical conditions, we examined oncogenic effects of LRIG1 loss in NPC cells by siRNA knockdown. Finally, we provide evidence that malignant behavior of LRIG1 knockdown cells was greatly decreased by treatment with specific inhibitors against components of the EGFR-MAPK-SPHK1 signaling pathway.
RESULTS
LRIG1 downregulation correlates with EGFR activation and poor clinical outcome in human head and neck cancers Our previous study found a significant association between LRIG1 deletion and poor clinical outcome in NPC patients. 3 To examine LRIG1 protein levels, we performed immunohistochemistry on tissue microarrays containing 44 metastatic NPC tumor samples. LRIG1 immunoreactivity was very intense in adjacent non-tumor epithelium, but only weakly positive in 65.9% (29 of 44) and undetectable in 34.1% (15 of 44) NPC samples ( Figure 1a ). Though no correlation emerged between LRIG1 loss and total EGFR levels (data not shown), NPC tumors with undetectable LRIG1 had higher phospho-EGFR (pEGFR) levels than those with positive LRIG1 staining (86.7 vs 13.8%, Po0.001, Figure 1a ), portending a negative regulatory role of LRIG1 in EGFR signaling. KaplanMeier survival analysis indicated a significant correlation (P ¼ 0.038) between low levels of LRIG1 and poor clinical outcome: NPC patients with positive LRIG1 staining exhibited a longer median survival time (108.6 months) than those with undetectable LRIG1 (33.8 months) (Figure 1b ). In agreement with these findings for NPC, cDNA microarray data from OSCC samples showed reduced LRIG1 expression in tumors compared with adjacent nontumor epithelium (Po0.001) ( Figure 1c) .
Next, we analyzed LRIG1 protein levels in head and neck cancer cell lines by western blot. Supplementary Figure S1 shows LRIG1 markedly downregulated in five NPC and four OSCC cell lines tested compared with the non-transformed nasopharyngeal NP460hTert and oral CGHNK6 cells. These indicate that LRIG1 downregulation is common in head and neck cancer patients, along with bad prognosis. LRIG1 deletion may trigger oncogenic signals promoting the development of head and neck cancers.
LRIG1 induction in NP cells reduces cell growth in vitro and tumorigenicity in vivo To characterize the role of LRIG1 in head and neck cancers, we established stable Tet-off inducible clones in TW01 cells, with LRIG1 expression barely detectable (Supplementary Figure  S1) .Western blots confirmed that LRIG1 expression could be turned on/off under the control of tetracycline-response element in clones TW01-LG1/a and TW01-LG1/b (Figure 2a) . Tetracycline cannot induce the expression of LRIG1 in vector transfectants (Supplementary Figure S2) . The LRIG1 expression level of TWO1-LG1/b cells is much higher than those of the untransformed NP460hTert cells. So we used TW01-LG1/a cells, which have a near normal LRIG1 expression level, for experiments. Figure 2b shows that LRIG1 induction significantly reduced the proliferation rate of TW01-LG1/a cells as early as 24 h after LRIG1 induction. Cell cycle analysis and annexin V staining indicated a tendency of G2/M arrest triggered by LRIG1 expression (Supplementary Figure S3a) , which led to the accumulation of cells in the sub-G1 population and cell death (Supplementary Figure S3b) . To determine whether LRIG1 controls tumor growth in vivo, we used a xenograft model in immunocompromised (nu/nu) mice by injecting subcutaneously with TW01-LG1/a cells and found that, compared with the noninduced group (LRIG1 off), LRIG1-expressing tumors (LRIG1 on) showed a much slower growth rate ( Figure 2c ) and lower tumor weight (P ¼ 0.008, Figure 2d ). On the other hand, we turned on LRIG1 has negative regulatory roles in oncogenic signaling by downregulation of EGFR ligands and SPHK1 To identify cancer-related genes and pathways regulated by LRIG1, we performed time-course microarray experiments with TW01-LG1/a cells during the period of LRIG1 induction. Significant transcriptional change was found 36 h after LRIG1 was turned on. Venn diagram analysis showed 46 genes overlapping with either an ascending or descending trend in mRNA expression level (Figure 3a) , which could be further validated by quantitative RT-PCR (Figures 3c and 4a and Table 1 ). Functional annotation analysis by PANTHER classification system (http://www.pantherdb.org) indicated diverse targets regulated by LRIG1 at transcriptional level ( Figure 3b and Table 1 ). In addition to enhancing EGFR degradation, the transcription of EGFR ligands/activators, such as amphiregulin (AREG), neuregulin 1 (NRG1), transforming growth factor-alpha (TGFA), and heparinbinding EGF-like growth factor (HBEGF), was reduced in response to LRIG1 induction (Figures 3b and c) . Consistent with prior findings, 16, 19 LRIG1 induction was accompanied in a timedependent manner by enhancing EGFR degradation and reducing phosphorylation of EGFR and MAPK (Figure 3d ). Expression of sphingosin kinase 1 (SPHK1), a downstream target of MAPK, 25 was also reduced by LRIG1 induction (Figure 3d ). LRIG1 inhibits extracellular matrix remodeling by downregulation of SNAI2 and MMPs Microarray experiments also revealed several genes involved in extracellular matrix (ECM) remodeling, such as those coding for MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, ITGA2, LAMB3, AMIGO2 and GJB5, accounting for the major group of LRIG1 targets (Figures 3b and 4a , and Table 1 ). Notably, expression of epithelial-to-mesenchymal transition marker SNAI2 was also reduced (Figures 3d and 4a) , suggesting that LRIG1 has a role in ECM remodeling. Subsequent western blot analysis using anti-MMP antibody array demonstrated a reducing trend of several MMPs at protein level, including MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-10 and MMP-13, upon LRIG1 being turned on. Supplementary Figure S4 shows whole images of MMP protein arrays at different color-development time points. Interestingly, the level of TIMP2, an MMP inhibitor, was significantly increased ( Figure 4b ). As phospho-MAPK (pMAPK) can be translocated into cell nucleus and act as a transcriptional regulator, 26 we examined whether pMAPK was directly responsible for reduced expression of LRIG1 targets. Chromatin immunoprecipitation (ChIP) analysis with anti-pMAPK antibodies revealed that LRIG1 induction significantly attenuates binding of pMAPK-associated transcription factors to promoter regions of MMP-1, MMP-3 and MMP-10 ( Figure 4c ). This finding suggests a novel transcriptional role of LRIG1 in regulating the expression of ECM factors, at least in part mediated via transcriptional regulation by pMAPK. Subsequent cell morphology analyses revealed a spread-out squamous cell shape in LRIG1 turned-on cells as compared with spindle-like shape in LRIG1 turned-off cells (Figure 4d ). Immunofluorescence staining revealed activated integrin (Figure 4e ), a hallmark of active ECM remodeling, in LRIG1 turned-off, but not in LRIG1 turned-on cells. These results support a regulatory role of LRIG1 in ECM remodeling. LRIG1 knockdown promotes oncogenicity, which can be suppressed by MAPK and SPHK1 inhibitors According to our findings, we proposed that the aggressiveness of cancer cells caused by LRIG1 loss might be suppressed by treatment with MAPK or SPHK1 inhibitors. To test this hypothesis, we used specific siRNA (siLRIG1) to knockdown LRIG1 expression in TW06 cells, which showed the highest LRIG1 levels among head and neck cancer cell lines tested (Supplementary Figure S1) . Western blot confirmed the robust effect of siLRIG1 on LRIG1 expression and that levels of pEGFR, pMAPK, SPHK1, and SNAI2 were all raised by LRIG1 knockdown (Figure 5a ). Increased SNAI2 levels and decreased E-cadherin levels (Figure 5a ) support the finding that cells with low LRIG1 expression have a spindle-like shape, while those with high LRIG1 levels have a squamous celllike shape (Figure 4d ). Anchorage-independent growth assay showed more and larger colonies formed by cells transfected with siLRIG1 than those transfected with scrambled control (Figure 5b ), suggesting that LRIG1 downregulation led to the acquisition of survival advantages in head and neck cancer cells. Interestingly, such effect was significantly decreased by treatment with MAPK inhibitor U0126 or SPHK1 inhibitor SK1-I (Figure 5b ). Although U0126 treatment slightly inhibits the clonogenicity of scrambled control cells, SK1-I has no effect on TW06 cells (Figure 5b ). Transwell migration (Figure 5c ) and invasiveness ( Figure 5d ) were significantly enhanced by LRIG1 knockdown, and these effects were both markedly inhibited by U0126 or SK1-I. Treatment of U0126 and SK1-I had no significant inhibitory effect on the migration and invasion of the scrambled control cells. It should be noted that, at the concentrations used (3 mM), U0126 or SK1-I had only a minor or undetectable cytotoxic effect on TW06 cells (Supplementary Figure S5) . In addition, empty vector transfectant derived from TW01 (TW01-Vec) showed no change in protein levels of pMAPK and SPHK1 after removal of doxycycline (Supplementary Figure S2) . These findings suggest that loss of LRIG1 expression is the major cause of MAPK and SPHK1 activation. To confirm results from culture experiments, we performed IHC staining against SPHK1 or pMAPK with graft tumors. Although tumors in LRIG1 turned-on group gradually lost LRIG1 expression after long-term clonal evolution, IHC results showed lower immunointensity of anti-SPHK1 and anti-pMAPK in the LRIG1-positive area than the ones in surrounding LRIG1-negative tissue (Supplementary Figure S6) . Our results support a cross-talk among EGFR, MAPK and SPHK1 that are regulated by LRIG1, and prove the association of LRIG1 downregulation with aggressiveness of head and neck cancers.
DISCUSSION
The present study provides the first evidence that LRIG1 downregulation promotes malignant characteristics in head and neck cancers by enhancing EGFR-MAPK-SHPK1 signaling and the associated ECM remodeling activity. Our data also demonstrate that LRIG1 downregulation serves as a prognostic marker for aggressive NPC (Figure 1b) . A Tet-off inducible system revealed MMPs and SPHK1 as direct downstream targets of LRIG1 and that the induction of LRIG1 is associated with low SPHK1 and MMP expression (Figures 3 and 4 , and Table 1 ). In addition, LRIG1 was shown to regulate transcription by reducing the expression of pMAPK and possibly other transcriptional factors (Figure 4c ). The increased expression of LRIG1 changed gene expression profiles, leading to a dynamic shift in the cellular signaling network from oncogenic to tumor-suppressing (Figure 3a) . These findings might explain why LRIG1 knockdown conferred advantages for tumor growth in mice, with larger tumors being seen in the LRIG1-off than in the LRIG1-on group (Figures 2c and d) .
Based on our data, we proposed a model for the role of LRIG1 in a positive feedback inhibitory loop in EGFR-MAPK-SPHK1 signaling and ECM remodeling ( Figure 6 ). In the presence of LRIG1, activation of EGFR and MAPK is attenuated, thus reducing transcription of EGFR ligands/activators by lowering levels of pMAPK or other unidentified transcriptional factors, resulting in further attenuation of EGFR signaling. In addition, the decreased expression of MMPs reduces ECM remodeling activity and inhibits the release of EGFR ligands/activators sequestered by ECM, which also leads to the inhibition of EGFR signaling. Moreover, decreased SPHK1 levels may reduce production of S1P, which binds to G-protein-coupled S1P receptors (S1PRs) that can transactivate other receptor-type tyrosine kinases (RTKs) including EGFR. 27 Thus, increased LRIG1 expression may not only attenuate EGFR-MAPK signaling, but also trigger a positive feedback inhibitory loop that further downregulates EGFR-MAPK-SPHK1 signaling. In contrast, the loss of LRIG1 in NPC cells will lead to tumor aggressiveness as a consequence of higher activation of EGFR-MAPK-SPHK1 signaling and enhancement of ECM remodeling activity. These findings suggest that MAPK and SPHK1 are potential therapeutic targets for tumors with LRIG1 loss.
SPHK1 catalyzes the conversion of sphingosine to sphingosine-1-phosphate (S1P), a bioactive lipid molecule that mediates S1P signaling by binding to SIP receptors. A handful of studies have shown that various types of human cancers acquire survival advantage, aggressiveness and chemotherapy resistance via nononcogenic addiction to S1P signaling. 28, 29 Because of the overexpression/activation of SPHK1 in cancer cells, SPHK1 has been cited as an emerging target for cancer therapy. 30, 31 Activation of EGFR-MAPK signaling is one of the mechanisms to increase SPHK1 activity, both at the level of expression and phosphorylation. 25 In addition, hyperactivation of EGFR signaling has been linked to the development of head and neck cancers by various approaches including functional genomics, quantitative phosphoproteomics and clinical association studies.
24,32,33 S1P signaling can activate G-protein-coupled S1PRs that subsequently transactivate EGFR in the presence of MMPs and HBEGF. 27 Our findings uncovered a novel reciprocal mechanism of signaling cross-talk between EGFR-MAPK-SPHIK1 and S1PR signaling in head and neck cancers, and LRIG1 has a key regulating role in this signaling network (Figure 6 ).
The signaling strength and duration of EGFR activation are controlled by multiple circuits of positive and/or negative feedback regulation. One such mechanism entails greater MMP activity in the ECM, whereas enhancement of ECM remodeling activity could be accompanied by local release of ECM-sequestered growth factors, cytokines and receptor tyrosine kinase ligands without de-novo protein synthesis. 34, 35 In head and neck cancers, EGFR amplification and LRIG1 (chromosome 3p) deletion are pathogenic events frequently observed in tumor tissues. 3, 5, 23 Clinically, both EGFR overexpression and LRIG1 downregulation correlate with a poor clinical outcome; 36 biologically, LRIG1 acts as a negative regulator to suppress EGFR-MAPK-SPHK1 signaling and ECM remodeling by positive-feedback inhibitory regulation ( Figure 6 ). Our study suggests that low levels of EGFR negative regulators, such as LRIG1 deletion, may elicit full oncogenic signaling, resulting in a permissive environment for tumor onset and progression.
In addition to its role as negative regulator for EGFR, LRIG1 was recently identified as a potent stem cell marker for non-cycling, long-lived populations located at the interfollicular epidermis 37, 38 or crypt base of the intestine. 39, 40 Genetic ablation of LRIG1 disturbs epithelial homeostasis and increases proliferative capacity of stem cells, 41 which may contribute to tumor formation. These findings raise the possibility that LRIG1 À / À cells harbor a mesenchymal phenotype to promote cancer progression and metastasis in combination with other genetic alterations, which warrants further investigation. Our results showed that the expression of SNAI2, an epithelial-to-mesenchymal transition marker, was induced in LRIG1 knockdown cells, while the expression of epithelium marker E-cadherin was dramatically reduced (Figure 5a ). In agreement with this finding, morphological analyses showed that LRIG1 controls cell shape/architecture ( Figure 4d ). As SPHK1-S1P signaling, 42 MMPs and ECM remodeling [43] [44] [45] have also been linked to epithelial-tomesenchymal transition, it will be interesting to investigate how LRIG1 regulates epithelial-to-mesenchymal transition in promoting aggressive phenotypes, such as metastasis and resistance to radio-/chemotherapy. Furthermore, differential subcellular protein localization or compensatory feedback mechanisms might account for LRIG1 protein upregulation in some tumor types. 46 This suggests that the subcellular localization of LRIG1 may determine its function in oncogenesis. The significance of specific subcellular localization of LRIG1 needs further investigation to elucidate the role of LRIG1 in human cancer.
In summary, our study suggests novel functions for LRIG1 in regulating cellular mobility and metastasis via EGFR-MAPK-SPHK1 signaling and ECM remodeling. Through transcriptional regulation and signaling transaction, LRIG1 is involved in a positive feedback loop that may determine cancer development. Inhibitors of MAPK or SPHK1 signaling components may be considered as candidate drugs for treating patients whose tumors show chromosome 3p/LRIG1 loss.
MATERIALS AND METHODS

Cell lines and reagents
Inhibitors U0126 and SK1-I (BML-258) were purchased from Sigma (St Louis, MO, USA) and Enzo Life Sciences (Farmingdale, NY, USA), respectively. Two established human NPC cell lines, TW01 and TW06, 47 were used in this study and cultured in Dulbecco's minimal essential medium containing 10% fetal calf serum at 37 1C under 5% CO 2 . Immunohistochemistry and western blot was performed using antibodies against human LRIG1 (Abcam, Cambridge, UK), EGFR, p-EGFR(1068Y) or SNAI2 (Cell Signaling, Danvers, MA, USA), MAPK and phospho-MAPK (pMAPK) (Merck Millipore, Billerica, MA, USA), SPHK1 (Abnova, Taipei, Taiwan), single-stranded DNA (ssDNA) (ENZO Life Sciences), integrin-b1 or GAPDH or a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). ECM proteins including MMP-1, -2, -3, -8, -9, -10 and Figure 6 . Model outlining the role of LRIG1 in a positive feedback inhibitory loop in the regulation of EGFR-MAPK-SPHK1 signaling and ECM remodeling. Sph, sphingosine; S1P, sphingosine-1-phosphate; S1PR, sphingosine 1-phosphate receptor.
-13, and their inhibitors TIMP-1, -2, and -4 were measured by antibody array (RayBio MMP human array 1, RayBiotech, Norcross, GA, USA) following the manufacturer's protocol and quantified on an ImageQuant LAS4000 (GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Human tumor tissues and immunohistochemistry
Tissue microarrays containing samples of forty-four metastatic NPC tissues and two normal oral epithelia were described previously. 3 Four representative cores from each formalin-fixed paraffin-embedded tumor were arranged on tissue microarrays for immunohistochemistry.
Statistical analysis and clinical correlation
Clinical information about NPC samples analyzed in this study, including tumor site, clinical stage, treatment history, recurrent status and five-year survival, was collected from clinical notes. The overall survival time was defined as the number of months between diagnosis and death or between diagnosis and the most recent follow-up. All calculations and statistical analyses were carried out using the SAS/STAT software package (SAS Institute, Cary, NC, USA) and plotted as survival curves using the Kaplan-Meier method. With this method, P-values o0.05 were considered significant.
Quantitative real-time PCR
The PCR primers were designed by the Universal Probe Library Assay Design Center (https://www.roche-applied-science.com). Quantitative real-time PCR was carried out on an ABI 7900HT sequence detection system (Applied Biosystems, Carlsbad, CA, USA) using a FastStart Universal Probe Master Kit (Roche Applied Science, Indianapolis, IN, USA). Fold changes in expression of target genes in the experimental sample relative to that in the control sample were calculated by normalization to ACTB or GAPDH levels.
Transfection and siRNA knockdown LRIG1 was knocked down in TW06 cells by Dharmacon ON-TARGET plus SMART pool (Dharmacon, Lafayette, CO, USA), with ON-TARGET plus siCONTROL non-targeting pool as the control. Cells were transiently transfected with 100 nM siRNA using Turbofect (Fermentas/Thermo Scientific, Waltham, MA, USA); then, the medium was replaced 8 h after transfection and the cells were incubated for a further 16-24 h.
Generation of stable LRIG1-inducible clones
An inducible system was generated in TW01 cells by transfection with tetracycline-controlled transactivator (tTA) expression vector. Full-length LRIG1 cDNA (tagged with V5 at C-terminus) was cloned into a pBI-inducible vector (Clontech, Mountain View, CA, USA), and these expression vectors were subsequently introduced into TW01 cells. For controls, the empty vector was introduced into TW01-tTA cells. Two TW01 transfectants, TW01-LG1/a and TW01-LG1/b, were generated by selection with G418 and hygromycin. Ectopic expression of LRIG1 was controlled by tetracyclineresponsive element in the promoter, with the genes being turned on in a doxycycline-free and turned off in a doxycycline-containing medium. Cell clones were validated by western blot and immunostaining.
Tumor xenografts in nude mice LRIG1-inducible TW01-LG1/a cells were injected subcutaneously into athymic nu/nu mice (5 Â 10 6 cells per injection, two injection sites per mouse, five mice per group). The LRIG1 turned-off control mice were injected intraperitoneally with doxycycline (125 mg/mouse) every day to suppress LRIG1 expression, while the LRIG1 turned-on group was injected with the same volume of phosphate-buffered saline. Tumor volume was measured every 3 days, and tumors were excised and weighed on Day 43.
Microarray analysis
Cellular RNA was harvested using an RNeasy kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions. A WT cDNA Synthesis Kit and WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA, USA) were used to generate amplified and labeled sense cDNA. The cDNA was hybridized to the Affymetrix Human Gene 1.0 ST Array according to standard Affymetrix protocol. Washing and staining steps were carried out using a GeneChip Fluidics station FS 450, and slides were scanned with an Affymetrix Gene Chip scanner 3000 7G system. Raw data were imported and analyzed by GeneSpring GX (Agilent Technologies, Santa Clara, CA, USA) to generate gene lists of differentially expressed (fold change in expression 42). Microarray data have been deposited in the National Center for Biotechnology Information's Gene Expression Omnibus (GEO), and are accessible through GEO with the accession number GSE37349 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37349).
Chromatin immunoprecipitation (ChIP) assay LRIG1-inducible TW01 cells after the gene being turned-on or turned-off were fixed by addition of 1% formaldehyde to culture medium, and cells were lyzed on ice with RIPA buffer (Sigma) containing protease inhibitors (Roche, Basel, Switzerland). Genomic DNA was fragmented by sonication to sizes ranging from 200-500 bp, then 1 mg of the fragments was incubated overnight at 4 1C with gentle rotation with 2 ml of anti-phospho-MAKP antibodies (ab50011 from Abcam) and 50 ml of protein A/G beads (Sigma). Then, protein-DNA complexes on beads were washed with RIPA buffer before elution with 1% SDS and 50 mM NaHCO 3 . ChIP-PCR for promoter regions of candidate genes was performed with primers shown in Supplementary Table 1.
Cell viability and proliferation assays Cells (1 Â 10 4 cells per well) were seeded overnight in 24-well plates, then placed in medium for the indicated time, then cell numbers were quantified by MTT assay. Briefly, MTT was added to cells at a final concentration of 0.5 mg/ml, then the cells were incubated at 37 1C for 3 h and lysed with DMSO, and the amount of formazan in each well was determined colorimetrically at 570 nm, using a spectrophotometer (Molecular Devices, Sunnyvale, CA, USA). Data from three independent experiments, each with four replicates, were averaged.
Morphology assay
Collagen-coated dish was prepared for morphology assay as described previously. 48 Briefly, tissue culture dishes (BD Biosciences, San Jose, CA, USA) were coated with 5 mg/ml of collagen Type I (BD Biosciences) in 0.02 N glacial acetic acid at 4 1C overnight, then the coating solution was aspirated out . The coated plate was washed with PBS once before use. TW01-LG1/a cells were seeded at a density of 2 Â 10 6 cells in 10-cm plates. After adhesion, cells were cultured in doxycycline-containing (LRIG1-off) or doxycycline-free medium (LRIG1-on). Phase-contrast pictures were taken every 24 h after turn on LRIG1 expression.
Soft agar assay
Cells were resuspended in culture medium containing 0.3% agarose at a density of 1 Â 10 5 cells in 6-well plates, then overlaid with 0.6% agarose and fed with fresh medium weekly for 3 weeks. After fixation and staining with violet blue, colonies were photographed and quantified using MetaMorph software (Molecular Devices). The experiment was performed three times, each time with four replicates.
Cell migration and invasion assays
An in-vitro cell migration assay was carried out using Trans-well chambers (8 mM pore size, BD Biosciences). For cell invasion assay, the chambers were coated with Matrigel (BD Biosciences). Cells were plated at a density of 5 Â 10 4 cells per chamber in a 24-well plate in serum-free Dulbecco's minimal essential medium in the top chamber according to the manufacturer's instructions, and Dulbecco's minimal essential medium containing 10% FCS was placed in the bottom chamber as the chemoattractant. After 24 h, cells that had migrated into, or invaded, the bottom chambers were stained with crystal violet and counted in four random fields using MetaMorph software (Molecular Devices). Data were averaged for three independent experiments, each with four replicates.
